Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors Daniel CastellanoEnrique GrandeEric Raymond Review Article 06 December 2014 Pages: 1099 - 1114
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients Toru AoyamaYusuke KatayamaSoichiro Morinaga Original Article 29 March 2015 Pages: 1115 - 1120
DNA intercalative 4-butylaminopyrimido[4′,5′:4,5]thieno(2,3-b)quinoline induces cell cycle arrest and apoptosis in leukemia cells Heggodu G. RohitKumarKittur R. AshaGopal M. Advi Rao Original Article 29 March 2015 Pages: 1121 - 1133
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer S. KordesH. J. KlümpenJ. W. Wilmink Original Article Open access 31 March 2015 Pages: 1135 - 1141
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites Mona DarwishMary BondJames P. Chovan Original Article Open access 01 April 2015 Pages: 1143 - 1154
A phase I study of resminostat in Japanese patients with advanced solid tumors Satoru KitazonoYutaka FujiwaraTomohide Tamura Original Article 07 April 2015 Pages: 1155 - 1161
Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis Rongbao ZhaoMichele VisentinI. David Goldman Original Article 07 April 2015 Pages: 1163 - 1173
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer Jin Won KimIn Sil ChoiDo-Youn Oh Original Article 10 April 2015 Pages: 1175 - 1182
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial D. YamamotoS. IwaseT. Yamaguchi Original Article 11 April 2015 Pages: 1183 - 1189
Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury Kazuhiko NakanoHitoshi AndoAkio Fujimura Original Article 11 April 2015 Pages: 1191 - 1197
Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe Bing-Bing YangPhuong Khanh MorrowDesmond Padhi Original Article 17 April 2015 Pages: 1199 - 1206
Functional polymorphisms of ITGB1 are associated with clinical outcome of Chinese patients with resected colorectal cancer Feng ZhouXiaojun HuangXianli He Original Article 17 April 2015 Pages: 1207 - 1215
Cisplatin resistance in human cervical, ovarian and lung cancer cells Jianli ChenCharalambos SolomidesHenry Simpkins Original Article 18 April 2015 Pages: 1217 - 1227
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test Moon Ki ChoiJung Yong HongMyung-Ju Ahn Original Article 23 April 2015 Pages: 1229 - 1236
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor Rosalba D’AlessandroMaria Grazia RefoloBrian Irving Carr Original Article 24 April 2015 Pages: 1237 - 1245
Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination Philip M. TedeschiYamini K. KathariJoseph R. Bertino Original Article Open access 28 April 2015 Pages: 1247 - 1252
Inhibition of SN-38 glucuronidation by gefitinib and its metabolite Wei LiYafei XingYong Liu Original Article 28 April 2015 Pages: 1253 - 1260
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs Takahisa KawamuraAkito HataNobuyuki Katakami Original Article 29 April 2015 Pages: 1261 - 1266
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002) Akito HataNobuyuki KatakamiShunichi Negoro Original Article 30 April 2015 Pages: 1267 - 1272
Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines Burcak KaracaMustafa DegirmenciRuchan Uslu Original Article 30 April 2015 Pages: 1273 - 1280
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial Takehiro KatoKeisuke UeharaThe Nagoya Surgical Oncology Group Original Article 01 May 2015 Pages: 1281 - 1288
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients Anna KoumarianouGeorgia KarayannopoulouGeorge Fountzilas Original Article 07 May 2015 Pages: 1289 - 1301
The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1 Ling-Chu ChangYung-Luen YuSheng-Chu Kuo Original Article 07 May 2015 Pages: 1303 - 1315
Targeting the EWS–FLI1 transcription factor in Ewing sarcoma R. TancrediA. ZambelliM. D’Incalci Short Communication 26 March 2015 Pages: 1317 - 1320